

6. Literaturverzeichnis

- Amann K, Gross ML, Ritz E. Pathophysiology underlying accelerated atherogenesis in renal disease: Closing in on the target. *J Am Soc Nephrol.* 2004;15:1664-1666.
- Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med.* 2004;351:1285-1295.
- Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. *J Am Soc Nephrol.* 2001;12:2747-2752.
- Annuk M, Lind L, Linde T, Fellstrom B. Impaired endothelium-dependent vasodilation in renal failure in humans. *Nephrol Dial Transplant.* 2001;16:302-306.
- Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. *J Am Soc Nephrol.* 1995;6:121-125.
- Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. *Lancet.* 2000;356:147-152.
- Becker BN, Himmelfarb J, Henrich WL, Hakim RM, Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. *J Am Soc Nephrol.* 1997;8:475-486
- Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. *Circulation.* 1997;96:3042-3047.
- Bianchi G. Hypertension in chronic renal failure and end-stage renal disease patients treated with haemodialysis or peritoneal dialysis. *Nephrol Dial Transplant.* 2000;15:105-110.
- Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM, Aortic pulse wave velocity index and mortality in end-stage renal disease. *Kidney Int.* 2003;63:1852-1860.
- Blacher J, Guerin AP, Pannier B, Marchias SJ, Safar ME, London GM, Impact of aortic stiffness on survival in end-stage renal disease. *Cirkulation* 1999;99:2434-2439

- Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. *Am J Kidney Dis.* 1998;31:607-617.
- Boaz M, Smetana S, Weinstein T, Matas Z, Gafer U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE); randomised placebo-controlled trial. *Lancet* 2000; 356:1213-1218.
- Busse R, Luckhoff A, Bassenge E. Endothelium-derived relaxant factor inhibits platelet activation. *Naunyn Schmiedebergs Arch pharmacol.* 1987;336(5):566-571
- Cavalcanti S, Ciandrini A, Severi S, Badiali F, Badiali F, Bini S, Gattiani A, Cagnoli L, Santoro A, Model-based study of the effects of the hemodialysis technique on the compensatory response to hypovolemia. *Kidney int.* 2004;65:1499-1510.
- Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. *Am J Nephrol.* 1996;16:35-44.
- Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. *Am J Kidney Dis.* 38 (Suppl 1): 2001;826-S29.
- Cook JP, Rossitich E Jr, Andon NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. *J Clin Invest.* 1991;88:1663-1671
- Correti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol.* 2002;39:257-265
- Daugirdas JT. Pathophysiology of dialysis hypotension: an update. *Am J Kidney Dis.* 2001;38(4 Suppl 4):S11-17
- Donauer J. Hemodialysis-induced hypotension; impact of technologic advances. *Semin Dial.* 2004;17:333-335
- Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. *J Am Soc Nephrol.* 9(12 Suppl): 1998; S16-S23.
- Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland. *Quasi-Niere Jahresbericht 2004/2005, Berlin, Deutschland*

- Gibbons GH, Dzau VJ: Mechanismen of Disease: The emerging concept of vascular remodelling. *N Engl J Med.* 1994;330:1431-1438.
- Goldman JM, Petterson MT, Kopotic RJ, Baker SJ. Masimo signal extraction pulse oximetry. *J Clin Monit comput* 2000;16:475-483
- Goldwasser P, Mittman N, Antignani A, Burrell D, Michel MA, Collier J, Avram MM. Predictors of mortality in hemodialysis patients. *J Am Soc Nephrol.* 1993;3:1613-1622.
- Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med.* 2000;342:1478-1483
- Griffith TM, Edwards DH, Lewis MJ, Henderson AH. Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation. *Eur J Pharmacol.* 1985 ;112(2):195-202
- Guerin AP, London GM, Marchias SJ, metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. *Nephrol dial Transplant.* 2000;15:1014-1021
- Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. *N Engl J Med.* 1998;339:799-805.
- Himmelfarb j, Hakim RM. Oxidative stress in uremia. *Curr Opin Nephrol Hypertens.* 2003;12:593-598.
- Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. *Kidney Int.* 1993;44:115-119.
- Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, Sunagawa H, Yoshihara K, Yoshi S, Toma S, Kowatari T, Wake T, Oura T, Fukiyama K. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. *Kidney Int.* 1997;51:1212-1217.
- Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thullez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. *Circulation.* 1995; 91:1314-1349
- Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. *J Am Soc Nephrol.* 2004a;15:442-453.

- Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD. A low serum iron level is a predictor of poor outcome in hemodialysis patients. *Am J Kidney Dis.* 2004b;43:671-684.
- Kalousova M, Sulkova S, Fialova L, Soukupova J, Malbohan IM, Spacek P, Braun M, Mikulikova L, Fortova M, Horejsi M, Tesar V, Zima T. Glycooxidation and inflammation in chronic hemodialysis patients. *Nephrol Dial Transplant.* 2003;18:2577-2581.
- Kao YH, Mohler Er, Arger PH, Sehgal CM. Brachial artery: measurement of flow-mediated dilatation with cross-sectional US-technical validation. *Radiology* 2003;228:895-900.
- Kosch M, Levers A, Barenbrock M, Fobker M, Schaefer RM, Rahn KH, Hausberg M. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress. *Nephrol Dial Transplant.* 2003;18:1370-1375
- LazarusJM, Owen WF. Role of biocompatibility in dialysis morbidity and mortality. *Am J Kidney Dis.* 1994;24:1019-1032.
- Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. *Nephrol Dial Transplant.* 2004;19:1-47.
- Mallick NP, Gokal R. Haemodialysis. *Lancet.* 1999;353:737-742.
- Marchais SJ, Guerin AP, Pannier BM, Delavaud G, London GM. Arterial compliance and blood pressure. *Drugs.* 1993;46:82-87.
- McVeigh GE, Bratteli CW, Morgan DJ, Alinder CM, Glasser SP, Finkelstein SM, Cohn JN. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. *hypertension.* 1999;33:1392-1398.
- Millasseau SC, Kelly RP, Ritter JM, Chowienczyk PJ. The vascular impact os aging and vasoactive drugs: comparison of two digital volume pulse measurements. *Am J hypertens.*2003;16:467-472
- Miura H, Wachtel RE, Liu Y, Loberiza FR Jr, Saito T, Miura M, Guttermann DD. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. *Circulation.*2001;103:1992-1998.

- Miyazaki H, Matsuka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. *Circulation*. 2000;101:1002-1006.
- Noris M, Todeschini M, Casiraghi F, Raccatello D, Martina G, Minetti L, Imberti B, Caspari F, Atti M, Remuzzi G. Effect of acetate, bicarbonate dialysis and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. *Am J Kidney Dis*. 1998;32:115-124.
- Olesen SP, Clapham DE, Davies PF. Haemodynamic shear stress activates a K⁺ current in endothelial cells. *Nature*. 1988;331:168-170.
- Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. *N Engl J Med*. 1993;329:1001-1006.
- Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. *Nephrol Dial Transplant*. 2000;15:58-68.
- Pastan S, Bailey J. Dialysis therapy. *N Engl J Med*. 1998;338:1428-1437.
- Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of the endothelium in the vasodilator response to flow in vivo. *Hypertension*. 1985;8:37-44.
- Rapaport RM, Murad F. Endothelium-derived and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP. *J Cyclic Nucleotide Protein Phosphor Res*. 1983;9(4-5):281-296.
- Raza K, Thambyrajah J, Townend JN, Exley AR, Hortas C, Filer A, Carruthers DM, Bacon PA. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lesson for atherosclerotic disease? *Circulation*. 2000;102:1470-1472.
- Ritz E, Deppisch R, Stier E, Hansch G. Atherogenesis and cardiac death: are they related to dialysis procedure and biocompatibility? *Nephrol Dial Transplant*. 1994;2:165-172.
- Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Cullerton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raji L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease; a statement from the American Heart

- Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation*. 2003;108:2154-2169.
- Saw J, Levin A, Gin K. Coronary artery disease in chronic kidney disease patients: assessing the evidence for diagnosis, screening and revascularization. *Can J Cardiol*. 2004;20:807- 813.
- Scholze A, Maier A, Stocks F, Karamohamad F, Vetter R, Zidek W, Tepel M. Sustained increase of extracellular calcium concentration causes arterial vasoconstriction in humans.
- Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine Reduces Plasma Homocysteine Concentration and Improves Pulse Pressure and Endothelial Function in Patients With End-Stage Renal Failure. *Circulation*, 2004;109, 369-374.
- Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McCellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. *Ann Intern Med*. 2002;137:555-562.
- Stenvinkel P, Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. *Nephrol Dial Transplant*. 2002;17:32-37.
- Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purif*. 2001;19:53–61
- Takazawa K, Tanaka N, Fujita M, et al., Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. *Hypertension* 1998;32:365-370.
- Tarng DC, Huang TP, Liu TY, Chen HW, Sung YJ, Wei YH. Effect of vitamin E-bonded membran on the 8-hydroxy 2'-deoxyguanosine level in leukocyte DNA of hemodialysis patients. *Kidney Int*. 2000;58:790-799
- Tepel M, Echelmeyer M, Orié NN, Zidek W. Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. *Kidney Int*. 2000;58:867-872.
- Tepel M, Oxidative stress - does it play a role in the genesis of essential hypertension and hypertension of uremia? *Nephrol Dial Transplant*. 2003;18:1439-1442.

- Tepel M, Markus van der Giet, Mario Statz; Joachim Jankowski, Walter Zidek. The antioxidant, acetylcysteine, reduces cardiovascular events in patients with end-stage renal failure. *Circulation*, 2003; 107: 992-995.
- van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. *Nephrol Dial Transplant*. 1998;13:1782-1786.
- Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. *Hypertension*. 2002;39:135-141
- Yeun JY, Kaysen GA. C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD. *Curr Opin Nephrol Hypertens*. 2000;9:621-630.
- Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. *Lancet*. 2001;358:2113-2117.